ArticleChest2026
Association of New and Growing Nodules With Malignancy in Follow-Up Screening for Lung Cancer: A Cohort Study.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CellVizioJournal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPulmonary nodules frequently are detected on low-dose CT (LDCT) imaging screening for lung cancer, although most are benign. Nodules detected on follow-up scans may be new or may show interval growth since the baseline screening. RESEARCH QUESTION: What is the magnitude of the risk of malignancy among new or growing nodules detected on follow-up LDCT imaging? STUDY DESIGN AND
methodsParticipants in the LDCT imaging screening arm of the National Lung Cancer Screening Trial with a baseline screening and at least 1 follow-up screening were included. The primary exposure of interest was nodules that were new or growing on the first follow-up LDCT imaging screening (T1). Other covariates included age, sex, family history of lung cancer, presence of emphysema, nodule size, attenuation, lobe location, and spiculation. The primary outcome was lung cancer diagnosis within 2 years of T1.
resultsAmong 24,604 participants with baseline and T1 follow-up LDCT imaging, 6,952 participants showed nodules present on T1, from which lung cancer was diagnosed within 2 years in 208 participants. Compared with preexisting nodules with no growth, new nodules were associated with nearly 4-fold greater odds of a lung cancer diagnosis within 2 years (OR, 3.9; 95% CI, 2.51-6.05; P < .0001); preexisting nodules with growth were associated with nearly 20-fold increased odds (OR, 19.7; 95% CI, 13.6-28.4; P < .0001).
interpretationOur results show that new and growing nodules detected on follow-up LDCT imaging are associated strongly with the risk of malignancy. The magnitude of these risks is substantially greater than for most other well-established risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.